Alumis Inc (ALMS)

• Market cap: $3.33B
• 1 day: -7.54%
• 5 days: -4.57%
• 1 month: -4.22%
• 3 months: 3.45%
• 6 months: -3.4%
• Year to date: 191.52%
• 1 year: 538.63%
• 5 years: 96.39%
• 10 years: 96.39%
• Sector: Healthcare
• Industry: Biotechnology

About: Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.

Employees: 227